Non-Invasive Baro Reflex Assessment – Combined System

NIBRA-CS is a comprehensive non-invasive system for Baro-reflex assessment and is a cloud-based IoT-enabled diagnostic device for autonomic neurofunction testing, specifically for the diagnosis of dysautonomia. It records the body's response via ECG (Lead II) and BP during activities such as changes in posture, Valsalva Maneuver, and sustained Hand Grip, as per approved medical literature. The device is completely standalone and portable, requiring low or no setup, and is aligned with EHR/EMR requirements and ABDM by the Govt. of India, taking the ABHA number of the patient. It is essential for diabetic people and the elderly and detects the degradation in coordination between the Nervous System and Vital Organs of the body.

Industry Domain
Healthcare Diagnostics

Development Stage
Product Validation

Application Field
Diabetes, Geriatric Care, Stroke Rehabilitation, Men's Sexual Health

Intellectual Property
Provisional Patent filed in India

Broad Description
IoT Device for Autonomic Neurofunction Testing



Value Proposition
- Essential test for diabetic people and the elderly to avoid potentially fatal medical, social and economic impacts on the patient and their family as a result of the inevitable degradation of health caused by undetected Neuropathies.
- Detects Dysautonomia, a condition that affects the interactions between the autonomic nervous system and vital organs.
- Non-invasive, cloud-based and portable device that requires low or no setup.
- Essential for all diabetologists and geriatric clinics. This has a significant role in the evaluation of men's sexual health, as well as in determining the degree of rehabilitation of stroke patients.

Competitive Advantage
- The device is cloud-based and IoT-enabled, making it easy to use and accessible from anywhere.
- This is completely stand-alone and does not require any laptop or computer to operate, unlike other devices in this domain. This significantly reduces the cost involved.
- It has successfully completed individual parameter testing against gold-standard devices.
- The technology has received Ethics Committee clearance and the initial Phase III Clinical Trial was completed with 100+ subjects.